Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes

VERACYTE, INC.

2024-Q2 EPS reported $0.05 revenue$211,272,000

Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).
Net income $5.7M; adjusted EBITDA $24.0M (21% of revenue); generated $26.7M cash.
Record Decipher Prostate volume ~19,900 (NCCN guideline boost); Afirma volume ~15,700 (new Medicare coverage for Bethesda V).
Cash and cash equivalents $235.9M; three Decipher studies published including SEER-linked analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.